Dual Blockage of Both Pd-L1 and Cd47 Enhances the Therapeutic Effect of Oxaliplatin and Folfox in Ct-26 Mice Tumor Model

Dual Blockage of Both Pd-L1 and Cd47 Enhances the Therapeutic Effect of Oxaliplatin and Folfox in Ct-26 Mice Tumor Model Publisher Pubmed

Alimohammadi R¹ ; Mahmoodi Chalbatani G² ; Alimohammadi M³ ; Ghaffarinazari H⁴ ; Rahimi A⁵ ; Mortaz E¹ ; Mossafa N¹ ; Boon L⁶ ; Jalali SA¹

Source: Scientific Reports Published:2023

Abstract

Colorectal cancer is a poorly immunogenic. Such property can be reverted by using ICD. However, ICD inducers can also induce the expression of inhibitory checkpoint receptors CD47 and PD-L1 on tumor cells, making CRC tumors resistant to mainly CD8 T cell killing and macrophage-mediated phagocytosis. In this study, we examined the therapeutic effect of Oxaliplatin and FOLFOX regimen in combination with blocking antibodies against CD47 and PD-L1. FOLFOX and Oxaliplatin treatment lead to an increase in CD47 and PD-L1 expression on CT-26 cells invitro and invivo. Combining blocking antibodies against CD47 and PD-L1 with FOLFOX leads to a significant increase in survival and a decrease in tumor size. This triple combining regimen also leads to a significant decrease in Treg and MDSC and a significant increase in CD8 + INF-γ + lymphocytes and M1/M2 macrophage ratio in the tumor microenvironment. Our study showed triple combining therapy with FOLFOX, CD47 and PD-L1 is an effective treatment regimen in CT-26 mice tumor model and may consider as a potential to translate to the clinic. © 2023, The Author(s).

Related Docs

View other Related Docs

1. Tumor Immunology, Clinical Immunology (2022)

2. Radiation Dose and Schedule Influence the Abscopal Effect in a Bilateral Murine Ct26 Tumor Model, International Immunopharmacology (2022)

3. Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-Ctla-4 and Doxil Combination Therapy, International Journal of Nanomedicine (2020)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (5)

Mohammad Vaezi (1)

Style	Citing Format
MLA	Alimohammadi R, et al.. "Dual Blockage of Both Pd-L1 and Cd47 Enhances the Therapeutic Effect of Oxaliplatin and Folfox in Ct-26 Mice Tumor Model." Scientific Reports, vol. 13, no. 1, 2023, pp. -.
APA	Alimohammadi R, Mahmoodi Chalbatani G, Alimohammadi M, Ghaffarinazari H, Rahimi A, Mortaz E, Mossafa N, Boon L, Jalali SA (2023). Dual Blockage of Both Pd-L1 and Cd47 Enhances the Therapeutic Effect of Oxaliplatin and Folfox in Ct-26 Mice Tumor Model. Scientific Reports, 13(1), -.
Chicago	Alimohammadi R, Mahmoodi Chalbatani G, Alimohammadi M, Ghaffarinazari H, Rahimi A, Mortaz E, Mossafa N, Boon L, Jalali SA. "Dual Blockage of Both Pd-L1 and Cd47 Enhances the Therapeutic Effect of Oxaliplatin and Folfox in Ct-26 Mice Tumor Model." Scientific Reports 13, no. 1 (2023): -.
Harvard	Alimohammadi R et al. (2023) 'Dual Blockage of Both Pd-L1 and Cd47 Enhances the Therapeutic Effect of Oxaliplatin and Folfox in Ct-26 Mice Tumor Model', Scientific Reports, 13(1), pp. -.
Vancouver	Alimohammadi R, Mahmoodi Chalbatani G, Alimohammadi M, Ghaffarinazari H, Rahimi A, Mortaz E, et al.. Dual Blockage of Both Pd-L1 and Cd47 Enhances the Therapeutic Effect of Oxaliplatin and Folfox in Ct-26 Mice Tumor Model. Scientific Reports. 2023;13(1):-.
BibTex	@article{ author = {Alimohammadi R and Mahmoodi Chalbatani G and Alimohammadi M and Ghaffarinazari H and Rahimi A and Mortaz E and Mossafa N and Boon L and Jalali SA}, title = {Dual Blockage of Both Pd-L1 and Cd47 Enhances the Therapeutic Effect of Oxaliplatin and Folfox in Ct-26 Mice Tumor Model}, journal = {Scientific Reports}, volume = {13}, number = {1}, pages = {-}, year = {2023} }
RIS	TY - JOUR AU - Alimohammadi R AU - Mahmoodi Chalbatani G AU - Alimohammadi M AU - Ghaffarinazari H AU - Rahimi A AU - Mortaz E AU - Mossafa N AU - Boon L AU - Jalali SA TI - Dual Blockage of Both Pd-L1 and Cd47 Enhances the Therapeutic Effect of Oxaliplatin and Folfox in Ct-26 Mice Tumor Model JO - Scientific Reports VL - 13 IS - 1 SP - EP - PY - 2023 ER -

Science Communicator Platform

Authors

Abstract